Clinical Trial Update: Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants [Phase 3]

View source ↗

Summary

Phase 3 trial assessing a 13-valent pneumococcal conjugate vaccine given with DTaP in healthy Japanese infants has completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy Infants
• Pneumococcal Disease Prevention

Drugs mentioned

• 13-valent pneumococcal conjugate vaccine (PCV13) with DTaP (13-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Healthy Subjects | Phase 3 | Status: COMPLETED | Results posted: 2012-10-12